When people first go on these medications they lose muscle and fat (which is natural), but if they go off of them and gain weight back, its all fat
Although the FDA officially removed tirzepatide from the shortage list in December 2024 and semaglutide in February 2025, compounded prescribing has not abated
Medical Safety Issues Using retatrutide without medical supervision means: No monitoring for side effects or complications Inappropriate dosing without medical guidance Drug interactions that go undetected Emergency situations without proper medical support FDA-Approved Alternatives to Consider While waiting for potential retatrutide approval, several FDA-approved weight loss medications are available through legitimate medical channels: GLP-1 Receptor Agonists These medications work similarly to one component of retatrutides triple action: Semaglutide (Ozempic for diabetes and Wegovy for weight loss) Tirzepatide (GLP-1/GIP receptor agonist sold as Mounjaro for diabetes and Zepbound for weight loss) Liraglutide (Victoza for diabetes and Saxenda for weight loss) Orforglipron (Foundayo) Other Prescription Options Additional FDA-approved weight loss medications include: These medications require prescriptions from licensed healthcare providers who can properly evaluate your eligibility and monitor your progress
Polley pointed out that even patients with similar clinical profiles might prioritize different aspects of their health or quality of life
If left untreated, these disorders can restrict blood flow to the placenta, making it harder for the baby to get the nutrients it needs
Compounded medications can be very safe
